^
No biomarker
AML
azacitidine oral
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
venetoclax
Sensitive
:
A1
Roche Press Release - 2wk
IDH2 mutation + SRSF2 mutation
AML
venetoclax
Sensitive
:
C3
Blood Adv - 2wk
NRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
KRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
FLT3-ITD mutation
AML
quizartinib
Sensitive
:
C2
Haematologica - 3wk
FLT3 mutation
AML
gilteritinib
Sensitive
:
A1
IDH2 mutation
AML
enasidenib
Sensitive
:
A1
No biomarker
AML
glasdegib
Sensitive
:
A1
No biomarker
AML
cytarabine/daunorubicin liposomal formulation
Sensitive
:
A1
FLT3 mutation
AML
midostaurin
Sensitive
:
A1
CD33 positive
AML
gemtuzumab ozogamicin
Sensitive
:
A1
No biomarker
AML
decitabine
Sensitive
:
A1
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive
:
A1
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive
:
A1
No biomarker
AML
azacitidine
Sensitive
:
A1
IDH1 mutation
AML
ivosidenib
Sensitive
:
A1
No biomarker
AML
idarubicin hydrochloride
Sensitive
:
A1
IDH2 mutation
AML
venetoclax
Sensitive
:
A2
IDH1 mutation
AML
venetoclax
Sensitive
:
A2
FLT3-TKD mutation
AML
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
AML
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
AML
gilteritinib
Sensitive
:
A2
FLT3 mutation
AML
venetoclax
Sensitive
:
A2
FLT3-ITD mutation
AML
sorafenib
Sensitive
:
A2
No biomarker
AML
cytarabine
Sensitive
:
A2
RUNX1-RUNX1T1 fusion
AML
gemtuzumab ozogamicin
Sensitive
:
A2
CBFB-MYH11 fusion
AML
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3-TKD mutation
AML
gilteritinib
Sensitive
:
A2
No biomarker
AML
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our